During testing phase, the GPR43-OE group demonstrated a shorter time of latency 1 st entrance to target (27.14 ± 3.92 s vs. AD: 44.23 ± 4.41 s; p < 0.05; Fig. 2D), more target quadrant crossings (2.38 ± 0.38 vs. AD:1.50 ± 0.33; p < 0.05; Fig. 2E), and longer percentage target area time (25.63 ± 2.70% vs. AD:17.20 ± 2.04%; p < 0.05; Fig. 2F). This evidence concerns the gene FFAR2 and Alzheimer disease.